29th May 2018 09:00
Abzena plc
Notice of full year results
Cambridge, UK, 29 May 2018 - Abzena plc (AIM: ABZA, 'Abzena' or the 'Group'), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, will publish its full year results for the year to 31 March 2018 on Monday, 4 June 2018.
A presentation for analysts will be held at 09:30am on 4 June 2018 at the offices of Instinctif Partners (65 Gresham Street, London EC2V 7NQ).
-Ends-
Enquiries:
Abzena plc John Burt, Chief Executive Officer Julian Smith, Chief Financial Officer
| +44 1223 903498 |
Numis (Nominated Adviser and Broker) Clare Terlouw / James Black / Paul Gillam
| +44 20 7260 1000 |
N+1 Singer (Joint Broker) Aubrey Powell / Liz Yong
| +44 20 7496 3000 |
Instinctif Partners Melanie Toyne Sewell / Rozi Morris / Alex Shaw
| +44 20 7457 2020 |
Notes to Editors
About Abzena
Abzena (AIM: ABZA) provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products.
The term 'ABZENA Inside' is used by Abzena to describe products that have been created using its proprietary technologies and are being developed by its partners, and include Composite Human Antibodies™ and ThioBridge™ Antibody Drug Conjugates (ADCs). Abzena has the potential to earn future licence fees, milestone payments and/or royalties on 'ABZENA Inside' products.
Abzena offers the following services and technologies across its principal sites in Cambridge (UK), San Diego, California (USA) and Bristol, Pennsylvania (USA):
· Biology research services, including immunogenicity assessment of candidate biopharmaceutical products and bioassay development;
· Protein engineering to optimise biopharmaceutical product candidates, including humanization and deimmunization of antibodies and other therapeutic proteins;
· Cell line development for the manufacture of recombinant proteins and antibodies;
· Contract process development and GMP manufacture of biopharmaceuticals, including monoclonal antibodies and other recombinant proteins for preclinical and clinical studies;
· Contract synthetic chemistry and bioconjugation research services, focused on antibody-drug conjugates (ADCs);
· Proprietary site-specific conjugation technologies and novel payloads for ADC development;
· GMP manufacturer of ADC linkers, payloads & combined linker-payloads; and.
· GMP analytical services for biopharmaceutical manufacturing projects
For more information, please see www.abzena.com
Related Shares:
Abzena